A Phase 2 interventional study of LDE225 and Placebo in Basal Cell Carcinoma, Gorlin Syndrome and Nevoid Basal Cell Carcinoma Syndrome, sponsored by Novartis Pharmaceuticals. Completed at 6 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-19.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was a phase II, double-blind, randomized, proof-of-concept, dose-ranging trial evaluating the efficacy, safety and pharmacokinetics of oral LDE225 in treatment of adult patients with NBCCS. This was an exploratory study designed to demonstrate preliminary efficacy of LDE225 in this indication. This study included a Screening period of approximately 4 weeks, treatment period duration of 12 weeks with initial follow-up of approximately 6-8 weeks followed by a long-term follow-up period.
35 studies on the registry are indexed under Basal Cell Nevus Syndrome; 4 are open to participants now.
This study's enrollment of 10 is below the median of 24 across 25 interventional studies indexed under Basal Cell Nevus Syndrome.
Browse Basal Cell Nevus Syndrome studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Compared within Basal Cell Nevus Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Carcinoma, Basal Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 400 mg once daily.
Drug: LDE225
Participants received matching placebo.
Drug: Placebo
supplied as 100 mg capsules
supplied in capsules
Clinical Clearance Assessment of Main Target Basal Cell Carcinomas (BCCs)
The clinical response of the main target (and secondary target, as appropriate) BCC(s) to treatment was evaluated using the following 6-point scale comparing the assessment at the visit to the clinical presentation at Baseline: 0 = Worsening, 1 = No change, 2 = Slight clearance (1-25% improvement), 3 = Moderate clearance (26-75% improvement), 4 = Marked clearance (76-99% improvement),5 = Complete clearance (100% improvement) Complete clearance was defined as no clinical residual signs of carcinoma, as evaluated by the Investigator at a post-Baseline visit, with the exception of post-inflammatory changes such as minimal residual erythema or residual hyper-pigmentation or hypo-pigmentation or residual scarring.
Time frame: Day 113
Histological Clearance Assessment of Main Target BCCs
The main (and secondary, if appropriate) target BCC tumor area(s) was/were excised surgically and sent to a central laboratory for histological examination.
Time frame: day 113
Measure: Disease Burden by BCC Tumor Counts
BCC tumor counts were performed separately for five body regions: head and neck, trunk back, trunk front (including axillae and groin), upper extremities and lower extremities (including buttocks). During the counting, the BCC tumors, were categorized upon inspection by their longest diameter measurement (\<10 mm, 10-19 mm, 20-29 mm, and \>+30mm), and also by the type of BCC (superficial, nodular, other). The counts for all of the BCC type and size categories were determined (or estimated if many small lesions) for each body region. The body region counts were summated to provide the overall BCC tumor count.
Time frame: Baseline, day 85, and day 113
| Milestone | LDE225 | Placebo |
|---|---|---|
| Started | 8 | 2 |
| Safety anlysis set | 8 | 2 |
| Pharmacodynamic set | 7 | 2 |
| Completed | 8 | 2 |
| Not completed | 0 | 0 |
| Milestone | LDE225 | Placebo |
|---|---|---|
| Started | 8 | 2 |
| Completed | 7 | 0 |
| Not completed | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
The clinical response of the main target (and secondary target, as appropriate) BCC(s) to treatment was evaluated using the following 6-point scale comparing the assessment at the visit to the clinical presentation at Baseline: 0 = Worsening, 1 = No change, 2 = Slight clearance (1-25% improvement), 3 = Moderate clearance (26-75% improvement), 4 = Marked clearance (76-99% improvement),5 = Complete clearance (100% improvement) Complete clearance was defined as no clinical residual signs of carcinoma, as evaluated by the Investigator at a post-Baseline visit, with the exception of post-inflammatory changes such as minimal residual erythema or residual hyper-pigmentation or hypo-pigmentation or residual scarring.
| Participants | LDE225 | Placebo |
|---|---|---|
| Complete Clearance (100% Improvement) | 3 | 0 |
| Marked Clearance (76-99% Improvement) | 3 | 0 |
| Moderate Clearance (26-75% improvement) | 1 | 0 |
| Slight Clearance (1-25%) | 0 | 1 |
| Worsening | 0 | 1 |
The main (and secondary, if appropriate) target BCC tumor area(s) was/were excised surgically and sent to a central laboratory for histological examination.
| Percentage of participants | LDE225 | Placebo |
|---|---|---|
| Histological clearance | 57 | 0 |
| Complete clinical (up to day 85) & histological | 14 | 0 |
| Complete clinical (up to day 113) & histological | 29 | 0 |
BCC tumor counts were performed separately for five body regions: head and neck, trunk back, trunk front (including axillae and groin), upper extremities and lower extremities (including buttocks). During the counting, the BCC tumors, were categorized upon inspection by their longest diameter measurement (\<10 mm, 10-19 mm, 20-29 mm, and \>+30mm), and also by the type of BCC (superficial, nodular, other). The counts for all of the BCC type and size categories were determined (or estimated if many small lesions) for each body region. The body region counts were summated to provide the overall BCC tumor count.
| Number of BCC tumors | LDE225 | Placebo |
|---|---|---|
| Baseline | 566 | 510 |
| Day 85 | 341 | 571 |
| Day 113 | 309 | 619 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LDE225 - Core | — | 0/8 (0%) | 7/8 (87.5%) |
| Placebo - Core | — | 1/2 (50%) | 1/2 (50%) |
| LDE225 - Long Term Follow-up | — | 1/8 (12.5%) | 2/8 (25%) |
| Placebo - Long Term Follow-up | — | 0/2 (0%) | 0/2 (0%) |
| Event | LDE225 - Core | Placebo - Core | LDE225 - Long Term Follow-up | Placebo - Long Term Follow-up |
|---|---|---|---|---|
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/8 | 1/2 | 0/8 | 0/2 |
| CellulitisInfections and infestations | 0/8 | 0/2 | 1/8 | 0/2 |
| Event | LDE225 - Core | Placebo - Core | LDE225 - Long Term Follow-up | Placebo - Long Term Follow-up |
|---|---|---|---|---|
| Eyelid irritationEye disorders | 0/8 | 1/2 | 0/8 | 0/2 |
| ConstipationGastrointestinal disorders | 0/8 | 1/2 | 0/8 | 0/2 |
| Postoperative wound infectionInfections and infestations | 0/8 | 1/2 | 0/8 | 0/2 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 3/8 | 1/2 | 0/8 | 0/2 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/8 | 1/2 | 0/8 | 0/2 |
| NauseaGastrointestinal disorders | 2/8 | 0/2 | 0/8 | 0/2 |
| FatigueGeneral disorders | 2/8 | 0/2 | 0/8 | 0/2 |
| NasopharyngitisInfections and infestations | 2/8 | 0/2 | 0/8 | 0/2 |
| Blood creatine phosphokinase increasedInvestigations | 2/8 | 0/2 | 0/8 | 0/2 |
| HeadacheNervous system disorders | 2/8 | 0/2 | 0/8 | 0/2 |
| Age, Continuous(Years) | LDE225 | Placebo | Total |
|---|---|---|---|
| Mean | 50.5 ± 9.90 | 66 ± 2.00 | 53.6 ± 10.95 |
| Sex: Female, Male(Participants) | LDE225 | Placebo | Total |
|---|---|---|---|
| Female | 4 | 0 | 4 |
| Male | 4 | 2 | 6 |
The record gives a start of Apr 2011, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sonidegib